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Abstract
Introduction: In humans, a major component of natural killer (NK) and T cell target recognition depends on the
surveillance of human leukocyte antigen (HLA) class I molecules by killer immunoglobulin-like receptors (KIRs).
Aims: To implement the knowledge about the immunological genetic background of acute ischemic stroke
susceptibility in relation to the frequency of the KIR genes and HLA alleles.
Methods: Subjects with acute ischemic stroke and subjects without stroke were genotyped for the presence of KIR
genes and of the three major KIR ligand groups, HLA-C1, HLA-C2, and HLA-Bw4, both HLA-B and HLA-A loci.
Results: Between November 2013 and February 2016, consecutive patients with acute ischemic stroke were
recruited. As healthy controls, we enrolled subjects without acute ischemic stroke. Subjects with acute ischemic
stroke in comparison with controls showed a higher frequency of 2DL3, 2DL5B, 2DS2, and 2DS4 KIR genes and a
lower frequency of HLA-B-Bw4I alleles. Subjects without acute ischemic stroke showed a higher frequency of
interaction between KIR 2DS2 and HLAC2. We also observed a higher frequency of 2DL3 and 2 DL4 KIR genes in
subjects with atherosclerotic (LAAS) subtype. Multiple logistic regression analysis showed a protective effect
towards stroke of HLA-B-Bw4I and interaction between KIR 2DL2 and HLAC1 and 2DS2-HLAC2 and a detrimental
effect of 2DL2-HLA-C1_A interactions.
Conclusion: Our findings of a higher frequency of activating KIR genes seem to be consistent with findings
previously reported patients with coronary syndrome. This higher frequency of “proinflammatory” genes in subjects
with ischemic stroke could also explain the immunoinflammatory activation of the acute phase of stroke.
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Background and purpose
Evidence for the contribution of T cell-mediated immunity
to cardiovascular diseases has only recently emerged [1, 2].
T cells infiltrate atherosclerotic plaques, and in these sites,
proinflammatory immune responses mediated by CD4+
T-helper type 1 (TH1) and CD8
+ cytotoxic T lymphocytes
are preponderant [1–4]. Natural killer (NK) cells activating
or inhibition pathways mediated by human leukocyte anti-
gen (HLA) expression could have a potential detrimental or
protective role towards inflammation-mediated acute com-
plications of atherosclerosis such as acute ischemic stroke.
In humans, a major component of NK and T cell tar-
get recognition depends on the surveillance of human
leukocyte antigen (HLA) class I molecules by killer
immunoglobulin-like receptors (KIRs), a family of di-
verse activating or inhibitory receptors that are
expressed on the surface of NK cells and T cell subsets
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[5]. Different KIRs can transmit inhibitory or activating
signals to the cell, and combinations of KIR genes
synergize to generate genes with widely differing balance
between activating and inhibitory types.
KIR receptors have been reported as involved in the
susceptibility to several diseases, including celiac disease,
rheumatoid arthritis, systemic lupus erythematosus, in-
fectious diseases, and cancer [4, 5]. Our group previously
reported [8] that immunocompetent subjects carrying
the homozygous A haplotype or the HLABw4T allele are
at higher risk of developing symptomatic disease after
primary cytomegalovirus (CMV) infection.
Although HLA genes, as well as the innate immune
genes KIR, are considered to be important determinants
of T cell involvement in inflammation, few studies, to
our knowledge, evaluated their role in the clinical setting
of susceptibility of acute complications of atherosclerotic
disease [5, 6].
One study [7] reported that CD4+CD28null T cell clones
from patients with acute coronary syndrome (ACS)
expressed a broader spectrum of KIRs with preference for
the stimulatory variant, CD158j, and that CD4+ T cell
clones from patients acquired de novo expression of the
DAP12 molecule, an adapter chain that transmits
CD158j-derived signals. Consequently, these T cells ac-
quire cytolytic capability that may suggest T cell involve-
ment also in acute complication of atherosclerosis also
indicating a possible role of KIR genetic background in
regulation of inflammatory cell involvement in acute car-
diovascular event.
No study, to the best of our knowledge, analyzed the
relationship between KIR aplotype and HLA allele and
the risk of developing an acute ischemic stroke.
Study hypothesis
 The principal hypothesis of our study was that a
higher risk of developing an ischemic stroke may be
related to a higher frequency of some KIR genes and
their HLA ligands and of their interactions in
comparison with subjects without ischemic stroke.
 An additional hypothesis was that a higher risk of
developing certain subtypes of ischemic stroke may
be due to a higher frequency of some genetic
variants of KIR and their HLA ligands or of their
interactions.
Aim of the study
The aim of this analytical cross-sectional study was:
– To assess if genetic variants of KIR and their HLA
ligands may influence susceptibility to ischemic
stroke and its TOAST subtype and to implement the
knowledge about the immunological and genetic
background of acute ischemic stroke susceptibility in
connection with the expression of the KIR and HLA
alleles
– To further characterize immune-inflammatory de-
gree of the acute phase of ischemic stroke by means
evaluation of peripheral frequency of CD28 null cells
in a sample of patients with acute stroke in compari-
son with subjects without ischemic stroke
Materials and methods
Between November 2013 and July 2016, consecutive pa-
tients with acute ischemic stroke were recruited from
Internal Medicine with Stroke Care ward of Policlinico
“P. Giaccone”, University of Palermo and Pronto Soc-
corso Unit of Giuseppe Giglia Hospital, Cefalù (Pa-
lermo). As controls, we enrolled consecutive healthy
subjects admitted to our ward in the same recruitment
period and without acute ischemic stroke and without
exclusion criteria (see above).
Ischemic stroke has been defined as: “An episode of
neurological dysfunction caused by focal cerebral, spinal,
or retinal infarction lasting more than 24 hours” [8].
For stroke patients, we evaluated medical history,
12-lead ECG, 24-h electrocardiography monitoring,
trans-thoracic echocardiography, carotid ultrasound,
brain CT, or MRI at admission.
Patients and controls were excluded if they had one of
these exclusion criteria: rheumatologic disorders,
chronic inflammatory disease, acute systemic infections,
recent venous thrombosis, recent acute myocardial in-
farction (AMI) (within 3 months), and recent cerebro-
vascular event (TIA or stroke within 6 months).
Type 2 diabetes mellitus was determined using a clin-
ically based algorithm that considered age at onset, pre-
senting weight and symptoms, family history, onset of
insulin treatment, and history of ketoacidosis [9]. Hyper-
tension was defined according to the 2013 ESH/ESC
guidelines [10]. Hypercholesterolemia was defined as
total serum cholesterol ≥ 200mg/dL, and hypertriglyc-
eridemia as total serum triglyceride ≥ 150 mg/dL on the
basis of the National Cholesterol Education Program–
Adult Treatment Panel III reports [11, 12]. Coronary ar-
tery disease has been evaluated by means the presence
of clinical symptomatology of angina, myocardial infarc-
tion, or any previous coronary revascularization.
Cerebrovascular disease (TIA/ischemic stroke) has
been evaluated by means patient history, neurological
exam, and hospital records.
Ethical approval and consent to participate
This protocol study was approved by the Ethics Com-
mittee of the Policlinico P. Giaccone Hospital and of
Giuseppe Giglia Hospital, Cefalù (Palermo). All patients
gave their written informed consent to participate in the
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study, as well as for sampling and banking of the bio-
logical material.
Stroke subtype evaluation
The type of acute ischemic stroke was classified ac-
cording to the TOAST classification [13]: (1) large ar-
tery atherosclerosis (LAAS), (2) cardioembolic infarct
(CEI), (3) lacunar infarct (LAC), (4) stroke of other
determined etiology (ODE), and (5) stroke of undeter-
mined etiology (UDE).
Cell isolation, staining, and flow cytometry
Peripheral blood has been drawn at 48 h after symptom
onset and after informed consent had been obtained
from the patient or his/her authorized representative.
Peripheral blood mononuclear cells (PBMCs) have been
obtained by density gradient centrifugation using the
lymphocyte separation medium (ICN Pharmaceutical,
Costa Mesa, CA). This protocol yields an average PBMC
composition of 60% T cells, 15% monocytes/macro-
phages, 10% B cells, and 15% natural killer cells [29].
White cells were obtained from 2ml of peripheral
EDTA-anticoagulated venous blood. Cells were labeled
with human monoclonal anti-CD4 antibodies conjugated
with fluorescein isothiocyanate and anti-CD28 anti-
bodies conjugated with phycoerythrine (Becton Dickin-
son). Mouse IgG1 antibodies conjugated with fluorescein
isothiocyanate (IgG1-FITC) and IgG2a conjugated with
phycoerythrine IgG2a-PE (Becton Dickinson) were used
as the isotype controls. The samples were incubated for
30 min in the dark at ambient temperature, washed with
5% saline, and centrifuged. The pellet was suspended in
1% formalin. Expression of the CD28 receptor on lym-
phocytes was studied with a FACSCalibur flow cyt-
ometer (FACSCalibur/Sysmex XT1800i dual platform)
operating with CellQuest OS2 software. The population
of CD4+CD28null was expressed as a percentage of CD4
+ cells (CD4+CD28null and CD4+CD28+).
HLA and KIR genotyping
Peripheral whole blood samples were collected as indi-
cated, and genomic DNA was extracted from leukocytes
by a commercial kit (PureLink® Genomic DNA, Thermo-
Fisher Scientific, Waltham, MA, USA). Using the poly-
merase chain reaction sequence-specific primer
(PCR-SSP) technique, the DNA subjects with acute is-
chemic stroke and subjects without stroke were geno-
typed for the presence of the three major KIR ligand
groups, HLA-C1, HLA-C2, and HLA-Bw4, both HLA-B
and HLA-A loci (Epitop-TYPE kit; BAG Health Care
GmbH, Lich, Germany). HLA-C and Bw4 KIR ligand
groups were assigned directly by using specific oligo-
nucleotide primers to type the codon corresponding to
amino acid 80 for HLA-C (HLA-C1, Cw alleles with
asparagine at position 80; HLA-C2, Cw alleles with ly-
sine at position 80) and for HLA-Bw4 (Bw4-I, Bw alleles
with isoleucine at position 80; Bw4-T, Bw alleles with
threonine at position 80). KIR genotyping was per-
formed for both inhibitory and activating KIR using the
KIR-TYPE kit (BAG Health Care GmbH).
The following KIR genes were analyzed, which in-
cluded the inhibitory receptors KIR2DL1, 2DL2, 2DL3,
2DL5, 3DL1, 3DL2, and 3DL3; the activating receptors
2DL4, 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, and 3DS1; two
pseudogenes (2DP1 and 3DP1) and the common vari-
ants of KIR2DL5 (KIR2DL5A, KIR2DL5B); the KIR2DS4
alleles; and KIR3DP1 alleles. KIR gene profiles were de-
termined by the presence or absence of each KIR gene.
The detection of individual receptors Kir/HLA ligands
was performed with the sequence-specific primer
method. Therefore, the amplification occurs only if the
primers are complementary to the target sequence and
is then highlighted to agarose gel electrophoresis. The
specific primers were selected so as to detect single KIR/
HLA ligand genes.
Statistical analysis
Statistical analysis of quantitative and qualitative data,
including descriptive statistics, was performed for all
items. Continuous data are expressed as mean ± SD, un-
less otherwise specified. Baseline differences between
groups were assessed by the chi-square test or Fisher
exact test, as needed for categorical variables, and by the
independent Student t test for continuous parameters if
the data were normally distributed. If the data did not
show a normal distribution, a non-parametric test was
used (Mann Whitney’s U test). Logistic regression ana-
lysis examined the correlation between patient charac-
teristics (independent variables) and patient groups
(dependent variable) in simple and multiple regression
models. An overall sample size of 124 patients (62 for
each study group) has been calculated to document a
difference of at least 20% in the prevalence of KIR genes
and HLA alleles between the patient groups. The sample
sizes took into account a significance level of 5% and a
power of 80%.
Data were analyzed by IBM SPSS Software 22 version
(IBM Corp., Armonk, NY, USA). All p values were
two-sided, and p < 0.05 was considered statistically
significant.
Results
We recruited 149 subjects with acute ischemic stroke.
We subsequently excluded 33 patients with incomplete
data and 10 patients for exclusion criteria. In the end,
data from 116 patients with acute ischemic stroke and
66 subjects without acute ischemic stroke were analyzed.
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General and clinical characteristics of patients with
acute ischemic stroke and of subjects without acute is-
chemic stroke are listed in Table 1.
The mean age of patients with acute ischemic stroke
was 75.5 ± 11.6 years in subjects with stroke and 73.7 ±
10.7 years in subjects without acute ischemic stroke.
Subjects with acute ischemic stroke showed in com-
parison with subjects without stroke a similar prevalence
of hypertension, diabetes, hypercholesterolaemia, and
atrial fibrillation, whereas subjects with ischemic stroke
showed in comparison with subjects without acute
stroke a higher prevalence of previous stroke (48.3% vs
18.2%; p < 0.0001) and higher mean glucose blood levels
(7.99 ± 3.27 mg/dl vs 6.05 ± 1.91 mg/dl; p < 0.0001),
higher mean SBP values (151.4 ± 27.4 mm/Hg vs 132.1 ±
11.4 mm/Hg; p < 0.0001), higher SBP values (15 l.4 ± 27.4
vs 132.1 ± 11.4/Hg; p < 0.0001), higher mean WBC count
(9448.7 ± 4978.17 vs 7208.7 ± 2141.6; p < 0.0001), and
higher ESR (29.07 ± 17.5 mm/h vs 14.7 ± 9.16; p < 0.0001)
and CRP (3.84 ± 5.56 vs 1.7 ± 1.6; p = 0.004) mean values.
Subjects with acute ischemic stroke showed in com-
parison with subjects without ischemic stroke higher
peripheral percentage of CD4+ (50.21 ± 8.31% vs 34.12 ±
6.81%; p < 0.0001) and CD28null (5.70 ± 2.33% vs 2.78 ±
0.93%; p < 0.0001) cells; furthermore, subjects with
stroke showed higher serum levels of TNF-α (18.7 ±
3.28 pg/ml vs 12.34 ± 4.54 pg/ml; p = 0.035) and IL-6
(22.10 ± 12.21 pg/ml vs 4.22 ± 1.44 pg/ml; p < 0.0001)
(see Table 1).
KIR genotype analysis of patients with acute ischemic
stroke in comparison with subjects without ischemic
stroke showed a higher frequency of 2DL3 (74.1% vs
42.4% p < 0.0001), 2DL5B (33.6% vs 18.8%; p = 0.03),
2DS2 (37.9% vs 16.6%; p = 0.003), 2DS4 (41.3 vs 16.6; p
< 0.0001), and 3DP1 (14.6% vs 0; p < 0.0001) KIR genes
(see Table 2 and Fig. 1) and a lower frequency of 3DL1
Table 1 General, demographic, and clinical findings in subjects with acute ischemic stroke and in subjects without ischemic stroke
Variables Subjects with acute ischemic stroke (n 116) Subjects without acute ischemic stroke (n 66) p
Sex (M/F) (n) 59/57 29/37 0.43
Age (years) (mean ± ds) 75.5 ± 11.6 73.7 ± 10.7 0.28
Diabetes (n/%) 48 (41.37) 30 (45.4) 0.62
Hypertension (n/%) 103 (87.9) 53 (80) 0.12
Hypercholesterolaemia (n/%) 41 (35.34) 27 (40.90) 0.51
Hypertriclyceridaemia (n/%) 26 (22.41) 19 (28.78) 0.32
Atrial fibrillation (n/%) 53 (45.68) 28 (42.46) 0.67
Previous stroke (n/%) 56 (48.27) 12 (18.18) < 0.0001
Glucose blood levels (mmol/L) 7.99 ± 3.27 6.05 ± 1.91 < 0.0001
SBP (mm/Hg) (mean ± ds) 15 l.4 ± 27.4 132.1 ± 11.4 < 0.0001
DBP (mm/Hg) (mean ± ds) 82.05 ± 14.43 78.8 ± 6.6 0.094
WBC (mean ± ds) 9448.7 ± 4978.17 7208.7 ± 2141.6 < 0.0001
Neutrophil (%) (mean ± ds) 72.3 ± 10.7 61.87 ± 9.5 0.32
ESR (mm/h) (mean ± ds) 29.07 ± 17.5 14.7 ± 9.16 < 0.0001
CRP (mg/dL) (mean ± ds) 3.84 ± 5.56 1.7 ± 1.6 0.004
TOAST subtype
LAAS 45 (38.8)
Lacunar 27 (23.3)
CEI 40 (34.5)
ODE 4 (3.4)
NIHSS (mean ± sd)
SSSS (mean ± sd)
CD4+ cells (%) (mean ± sd) 50.21 ± 8.31 34.12 ± 6.81 < 0.0001
CD4+CD28− (%) (mean ± sd) 5.70 ± 2.33 2.78 ± 0.93 < 0.0001
TNF-α (pg/ml) (mean ± sd) 18.7 ± 3.28 12.34 ± 4.54 0.035
IL-6 (pg/ml) (mean ± sd) 22.10 ± 12.21 4.22 ± 1.44 < 0.0001
SBP systolic blood pressure, DBP diastolic blood pressure, WBC white blood cell, ESR erythrocyte sedimentation rate, CRP C-reactive protein, LAAS large artery
atherosclerotic stroke, CEI cardioembolic infarct, ODE other determined etiology, NIHSS National Institutes of Health Stroke Scale, SSS Scandinavian Stroke Scale
Score, CD4+ cluster of differentiation 4, CD28− cluster of differentiation 28 null cell, TNF-α tumor necrosis factor alfa, IL-6 interleukin-6
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(67.2% vs 89.3%; p < 0.0001), 3DL2 (67.2% vs 100%; p <
0.0001), 3DL3 (62.9% vs 100%; p < 0.0001), 2DS5 (14.6%
vs 51.5%; p < 0.0001), and 2DP1 (77.5% vs 100%) KIR
genes in comparison with subjects without stroke. No
difference was reported in the frequency of KIR haplo-
types between the groups.
With regard to HLA alleles, subjects without ische-
mic stroke showed in comparison with stroke sub-
jects a significantly higher frequency of HLA-B-Bw4I
alleles (65.1% vs 8.6%; p < 0.0001) (see Table 2 and
Fig. 1).
With regard to KIR-HLA ligand interactions, sub-
jects with acute ischemic stroke showed in comparison
with subjects without acute stroke a higher frequency
of interaction between KIR2DS2 and HLAC2 (25% vs
6.06%; p = 0.001) (see Table 3 and Fig. 1) and a lower
frequency of interaction between KIR2DL2 and
HLA-C1 (21.55% vs 40.9%; p = 0.007).
Multiple logistic regression analysis considering vari-
ables predictive of ischemic stroke showed the protective
effect of HLA-B-Bw4I alleles (B = − 3.649; p < 0.0001)
and of interaction between KIR2DL2 and HLA-C1 (B =
− 1.901; p = 0.004), whereas a detrimental effect was ob-
served with regard to interaction between KIR2DS2 and
HLAC2 (B = 2.687; p = 0.004) and between KIR2DL2
and HLA-C1_A (B = 1.847; p = 0.014) (see Table 4).
General, demographic, and clinical findings in subjects
with acute ischemic stroke in relation to TOAST sub-
type are listed in Table 5.
With regard to KIR gene frequency in relation to
TOAST subtype, we observed a higher frequency of
2DL3 (86.3% vs 62.9% vs 72.5%; p = 0.033), 2DL4 (88.8%
vs 59.25% vs 65%; p = 0.010), 3DL2 (82.2% vs 51.8% vs
62.5%; p = 0.016), and 3DL3 (80% vs 48.14% vs 55%; p =
0.015) KIR genes in subjects with LAAS subtype in com-
parison with subjects with other subtypes, whereas with
Table 2 Frequencies of KIR haplotypes and HLA alleles among individuals acute ischemic stroke and in subjects without stroke
Aplotipo KIR Subjects with acute ischemic stroke (n 116) Subjects without acute ischemic stroke (n 66) p
2DL1 (n/%) 64 (55.17) 43 (65.16) 0.21
2DL2 (n/%) 41 (35.34) 26 (39.3) 0.63
2DL3 (n/%) 86 (74.1) 28 (42.4) < 0.0001
2DL4 (n/%) 84 (72.4) 66 (100) < 0.0001
2DL5A (n/%) 14 (12.06) 12 (18.8) 0.27
2DL5B (n/%) 39 (33.6) 12 (18.8) 0.03
2DS1 (n/%) 24 (20.6) 18 (27.2) 0.36
2DS2 (n/%) 44 (37.9) 11 (16.6) 0.003
2DS3 (n/%) 31 (26.7) 17 (25.7) 1
2DS4 (n/%) 48 (41.3) 11 (16.6) 0.001
2DS5 (n/%) 17 (14.6) 34 (51.5) < 0.0001
3DL1 (n/%) 78 (67.2) 59 (89.3) 0.001
3DL2 (n/%) 78 (67.2) 66 (100) < 0.0001
3DL3 (n/%) 73 (62.9) 66 (100) < 0.0001
3DS1 (n/%) 60 (51.7) 37 (56.06) 0.64
2DP1 (n/%) 90 (77.5) 66 (100) < 0.0001
3DP1 (n/%) 17 (14.6) 0 < 0.0001
3DP1*003 (n/%) 73 (62.9) 66 (100) < 0.0001
KIR-aplotypes
HLA-A (n/%) 52 (44.8) 30 (45.4) 1.0
HLA-A+B (n/%) 62 (53.4) 37 (56.0) 0.76
HLA alleles
HLA-Bw4 T (n/%) 31 (26.7) 13 (19.6) 0.36
HLA-A-BW4 (n/%) 31 (26.7) 16 (24.2) 0.85
HLA-B-Bw4I (n/%) 10 (8.6) 43 (65.1) < 0.0001
HLA-C1 (n/%) 38 (32.7) 26 (39.3) 0.420
HLA-C2 (n/%) 36 (31.03) 19 (28.7) 0.86
KIR killer cell immunoglobulin-like receptor, HLA human leukocyte antigen
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regard to interactions between KIR and HLA alleles, we
observed only a higher frequency of the interaction be-
tween KIR2DL1 and HLA-C1 alleles in subjects with
cardioembolic stroke subtype (22.5% vs 4.4% vs 14.81%;
p = 0.047) (see Table 5 and Fig. 2).
Multiple logistic regression analysis considering vari-
ables predictive of TOAST subtype of ischemic stroke
showed a significant association between 2DL5A (B =
2.81; p = 0.03) and 3DL1 (B = 2.17; p = 0.02) KIR genes
and cardioembolic stroke, whereas with regard to HLA
alleles, only HLA-C1 allele (B = 2.36; p = 0.004) was sig-
nificantly associated with cardioembolic stroke (see Ta-
bles 6 and 7).
At multiple regression analysis, we also observed a
possible trend toward significance with regard to the
protective role of HLA-A-Bw4 HLA alleles (p = 0.05)
and of interaction between KIR 2DS2 and HLA-C2
alleles (p = 0.05) towards LAAS subtype of stroke
(see Table 7).
Discussion
Our study showed that subjects with acute ischemic
stroke in comparison with subjects without stroke were
more likely to have a higher frequency of 2DL3, 2DL4,
2DL5B, 2DS2, 2DS4, and 3DP1 KIR genes and a signifi-
cantly lower frequency of HLA-B-Bw4I allele.
The definition of an immunological genetic profile in
patients with acute ischemic stroke could better
characterize the pathogenesis of the disease, offering
new perspectives of diagnostic and therapeutic evalu-
ation. Considering the complexity of genetic studies, we
hypothesized that due to the high polymorphism of KIR
genes by contributing to the variability of the immune
response both innate and adaptive, these genes could be
a suitable subject of a study addressed to explain genetic
basis of inflammatory pathogenesis of ischemic stroke
and of its subtype.
Several studies have reported that susceptibility to is-
chemic stroke and its functional prognosis seems to be
Fig. 1 frequency of KIR genes and of interaction KIR-HLA in subjects with ischemic stroke
Table 3 Frequencies of KIR-HLA combinations among individuals with acute ischemic stroke and in subjects without stroke
HLA and KIR interaction Subjects with acute ischemic stroke Subjects without acute ischemic stroke p
2DL2-HLA-C1 (n/%) 25 (21.55) 27 (40.9) 0.007
2DL3-HLA-C1 (n/%) 38 (32.75) 22 (33.3) 0.93
2DS2-HLA-C1 (n/%) 37 (31.89) 23 (34.48) 0.94
2DS2-HLA-C2 (n/%) 29 (25.0) 4 (6.06) 0.001
2DL2-HLA-C2 (n/%) 26 (22.41) 11 (16.67) 0.34
2DS1-HLA-C2 (n/%) 15 (12.93) 5 (7.57) 0.42
2DL1-HLA-C1 (n/%) 16 (13.79) 7 (10.6) 0.52
2DL1-HLA-C2 (n/%) 17 (14.65) 13 (13.79) 0.41
KIR killer cell immunoglobulin-like receptor, HLA human leukocyte antigen
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influenced by systemic inflammatory processes and that
stroke patients with systemic inflammation exhibit clin-
ically poorer outcomes [14].
The KIRs (also known as CD158) are a family of re-
ceptors encoded by 14 polymorphic genes [15] seven of
which are inhibitory and seven of which are activating.
Although the current view focuses primarily on the im-
pacts of KIR expression on NK cell function, it is im-
portant to note that KIR are also expressed on subsets
of T cells, including invariant NKT cells, and can also
directly influence their function.
Furthermore, some authors [16–19] have shown that
the relative response of CD56bright and CD56dim NK cells
is associated with KIR genotype, providing the first dir-
ect evidence that KIR genotype may influence the NK
response to a wide range of non-viral pathogens.
In our study, we reported higher serum levels of IL-6
and TNF-α and higher percentage of peripheral CD4+
cells and CD4+CD28 null in subjects with acute ische-
mic stroke in comparison with subjects without stroke.
These findings are consistent with our own previous re-
sults [27, 33, 34] and with other previous studies report-
ing the role of an immune-inflammatory activation
involving inflammatory cytokines [20, 21] and CD4
+CD28 null T cell subsets [22–25] in the acute phase of
ischemic stroke. Thus, our finding of an increased per-
ipheral percentage of CD28null cells in peripheral blood
of subjects with ischemic stroke may be also related to
the higher prevalence of KIR gene activators such as 2S2
and 2DS4.
CD4+CD28null T cells are functionally distinct from
classical CD4 helper T cells. They do not express CD40
ligand, produce large amounts of IFN-γ, and express
granzyme B and perforin, giving them the capability to
lyse target cells [30, 31]. Their cytotoxic potential, as
well as expression of the NK cell marker CD57, suggests
that CD4+CD28null T cells share features with NK cells.
CD4+CD28null but not CD4+CD28+ T cells express KIR.
A direct role of CD4+CD28null T cells in vascular in-
jury has been suggested because these cells are also a
risk factor for inflammation and rupturing of athero-
sclerotic plaques in acute coronary syndromes [32].
These findings corroborate an inflammatory concep-
tion of ischemic stroke, although since inflammation has
a validated role in plaque instability events, inflamma-
tory mechanisms may explain atherothromboembolic
pathogenetic mechanisms of stroke.
In a previous study [32], we postulated that a potential
mechanism for the relationship between inflammation,
stroke pathogenesis, and stroke subtype pathogenesis
may be focused on the contribution of pro-inflammatory
gene polymorphisms (SNPs).
In our subjects with acute ischemic stroke in compari-
son with control subjects, we observed a higher preva-
lence of certain activators KIR gene (2DS2 and 2DS4)
consistent with findings of previous studies conducted in
patients with acute coronary syndrome [26–28] and un-
stable atherosclerotic plaques [29]. We have also re-
ported a higher prevalence of an inhibitor gene such as
2DL3, of one aplotype of uncertain behaviour such as
KIR2DL5B, and of one gene such as KIR2DL4 that is
both inhibitory and activating signaling. It is conceivable
to consider the prevailing KIR gene frequency of patients
with acute ischemic stroke as predominantly as
Table 4 Logistic regression model to predict the presence of acute ischemic stroke in relation to prevalence of KIR haplotypes
Variable Beta Exp(B) 95% confidence interval for Exp(B) p value
HLA-A-Bw4 0.16 1.18 0.42–3.26 0.745
HLA-A aplotype 0.17 1.19 0.48–2.9 0.702
HLA-C1 0.09 1.09 0.35–3.4 0.874
HLA-C2 0.55 1.73 0.53–5.69 0.361
HLA-B-Bw4T 0.30 1.35 0.44–4.11 0.593
HLA-B-Bw4I − 3.64 0.02 0.008–0.08 < 0.0001
2DL2-HLA-C1 − 1.90 0.149 0.041–0.55 0.004
2DL3-HLA-C1 0.32 1.37 0.50–3.75 0.529
2DS2-HLA-C1 0.68 1.97 0.67–5.83 0.216
2DS2-HLA-C2 2.68 14.68 2.33–92.4 0.004
2DL2-HLA-C2 0.13 1.14 0.34–3.84 0.825
2DS1-HLA-C2 − 0.27 0.75 0.21–2.64 0.667
2DL1-HLA-C1 0.37 1.45 0.34–6.07 0.607
2DL2-HLA-C1_A 1.84 6.33 1.46–27.47 0.014
2DL1-HLA-C2 0.03 1.03 0.30–3.59 0.953
KIR killer cell immunoglobulin-like receptor, HLA human leukocyte antigen
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Table 5 General, demographic, and clinical findings of KIR haplotype, HLA allele, and their combination frequencies in subjects with
acute ischemic stroke in relation to TOAST subtype
Variables LAAS (n 45) Lacunar (27) Cardioembolic (40) p
Male (n/%) 29 (64.4) 12 (44.4) 15 (37.5) 0.057
Hypertension (n/%) 39 (86.6) 24 (88.8) 36 (90) 0.85
Diabetes (n/%) 20 (44.4) 13 (48.14) 15 (37.5) 0.40
Hypercholesterolaemia (n/%) 24 (53.3) 6 (22.22) 10 (25) 0.011
Hypertriglyceridaemia (n/%) 12 (26.66) 5 (18.51) 9 (22.5) 0.84
Atrial fibrillation (n/%) 8 (17.77) 8 (29.62) 35 (87.5) 0.0001
Previous stroke (n/%) 21 (46.66) 13 (48.14) 21 (52.5) 0.90
2DL1 (n/%) 27 (60) 13 (48.14) 22 (55) 0.75
2DL2 (n/%) 20 (44.4) 7 (25.92) 12 (30) 0.20
2DL3 (n/%) 39 (86.6) 17 (62.96) 29 (72.5) 0.033
2DL4 (n/%) 40 (88.8) 16 (59.25) 26 (65) 0.010
2DL5A (n/%) 6 (13.33) 1 (3.73) 7 (17.5) 0.37
2DL5B (n/%) 13 (28.8) 11 (40.7) 14 (35) 0.76
2DS1 (n/%) 7 (15.5) 7 (25.9) 9 (22.5) 0.52
2DS2 (n/%) 14 (31.1) 12 (44.4) 17 (42.5) 0.61
2DS3 (n/%) 13 (28.8) 6 (22.2) 10 (25) 0.92
2DS4 (n/%) 20 (44.4) 10 (37.03) 16 (40) 0.90
2DS5 (n/%) 5 (11.11) 4 (14.81) 8 (20) 0.73
3DL1 (n/%) 34 (75.55) 13 (48.14) 28 (70) 0.073
3DL2 (n/%) 37 (82.22) 14 (51.85) 25 (62.5) 0.016
3DL3 (n/%) 36 (80) 13 (48.14) 22 (55) 0.015
3DS1 (n/%) 23 (51.1) 14 (51.85) 23 (57.5) 0.35
2DP1 (n/%) 39 (86.6) 19 (70.37) 30 (75) 0.26
3DP1 (n/%) 3 (6.66) 4 (14.81) 10 (25) 0.11
HLA-A-Bw4 (n/%) 8 (17.77) 9 (33.3) 12 (30) 0.33
HLA-A haplotype (n/%) 18 (40) 12 (44.4) 20 (50) 0.68
HLA-C1 haplotype (n/%) 13 (28.88) 5 (18.51) 19 (47.5) 0.069
HLA-C2 haplotype (n/%) 12 (26.66) 9 (33.3) 14 (35) 0.83
HLA-B-Bw4-T (n/%) 14 (31.11) 4 (14.81) 12 (30) 0.37
HLA-B-Bw4 I (n/%) 3 (6.66) 1 (3.7) 6 (15) 0.42
2DL2-HLA-C1 (n/%) 7 (15.5) 4 (14.81) 12 (30) 0.24
2DL3-HLA-C1 (n/%) 15 (33.3) 8 (29.62) 13 (32.5) 0.67
2DS2-HLA-C1 (n/%) 13 (28.87) 11 (40.74) 14 (35) 0.54
2DS2-HLA-C2 (n/%) 8 (17.77) 9 (33.3) 11 (27.5) 0.40
2DL2-HLA-C2 (n/%) 8 (17.77) 7 (25.92) 9 (22.5) 0.24
2DS1-HLA-C2 (n/%) 5 (11.11) 2 (7.40) 7 (17.5) 0.67
2DL1-HLA-C1 (n/%) 2 (4.4) 4 (14.81) 9 (22.5) 0.047
2DL2-HLA-C1 (n/%) 7 (15.5) 4 (14.81) 12 (30) 0.24
2DL1-HLA-C2 (n/%) 7 (15.5) 3 (11.11) 7 (17.5) 0.88
KIR killer cell immunoglobulin-like receptor, HLA human leukocyte antigen
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excitatory consistently with previous findings in patients
with coronary acute syndrome, whereas coexistent ex-
pression of the two inhibitor genes could be viewed as a
simple modulatory effect towards excitatory pathway
expression.
The function of stimulatory KIRs is unclear, and these
receptors are usually expressed in the context of several
inhibitory receptors. For the CD4+CD28null T cell clones,
some authors [33] recently demonstrated a costimula-
tory activity of CD158b-specific antibodies to enhance
proliferation and cytokine production [34], confirming
earlier reports that KIR2DS2 can function as a costimu-
latory molecule in response to suboptimal TCR trigger-
ing [35]. Furthermore, it has been reported in patients
with rheumatoid vasculitis [36] and in patients with an
acute coronary syndrome [37, 38] that CD4+CD28null T
cells expressed KIR2DS2 in the absence of opposing in-
hibitory receptors of the same specificity. Thus, in
CD4+CD28null T cells, the activity of KIR2DS2 may favor
the activation of autoreactive T cells involved in instabil-
ity mechanisms of atherosclerotic plaque and in ische-
mic neuronal damage.
With regard to HLA alleles, our patients with acute is-
chemic stroke showed in comparison with subjects with-
out stroke no significant difference in frequency of HLA
alleles, whereas subjects without ischemic stroke showed
in comparison with stroke subjects a significantly higher
frequency of HLA-B-Bw4I allele. The increased expres-
sion in control subjects without ischemic stroke of the
HLA-B with “Bw4I motif” that generally interacts with
inhibitory 3DL1 and 3DL3 receptors could represent a
further confirmation of predominantly pro-inflammatory
genetic background of subjects with stroke in
comparison with the anti-inflammatory genetic profile of
control subjects without ischemic stroke. To our know-
ledge, this is the first study to show that the KIR-ligand
group HLA-A-Bw4I can influence the susceptibility to
ischemic stroke and may also represent a possible patho-
genetic background of inflammatory damage in acute is-
chemic stroke. This effect may be mediated by the
activation of the inhibitory KIR3DL1, although an asso-
ciation with other HLA-B-Bw4 alleles [37, 38] that bind
the same KIR gene was not reported in this study.
Finally, multiple logistic regression analysis consider-
ing variables predictive towards the presence of acute is-
chemic stroke showed a protective effect of
HLA-B-Bw4I and of 2DL2-HLA-C1, and a detrimental
effect of 2DL2-HLA-C1_A and 2DS2-HLA-C2
HLA-KIR interactions.
These findings could confirm the protective role of an
anti-inflammatory genetic background such as the pres-
ence of the B-Bw4I motif.
Thus, our present study represents a first attempt to
bring in the context of an overall immune-inflammatory
view of point that leads cytokine and cell-dependent in-
flammatory mechanisms ischemic stroke occurrence to a
genetic background in terms of KIR receptor-ligand
HLA allele interactions. Thus, a greater degree of cyto-
kine and cell-mediated (NK cells or T cell subset such as
CD4+CD28null cells) inflammatory activation could be
also dependent by KIR genes responsible for activator
KIR receptors on these inflammatory cells.
Further research on other studies by our group will
be needed, and some studies are already been ad-
dressed to evaluate possible effects on the incidence
of recurrent ischemic events in relation to frequency
Fig. 2 Frequency of KIR genes and of interaction KIR-HLA in subjects with ischemic stroke in relation to TOAST subtype
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Table 6 Logistic regression model to predict TOAST subtype of acute ischemic stroke in relation of prevalence of KIR haplotypes
Variable Beta Exp(B) 95% confidence interval for Exp(B) p value
Lacunar subtype
2DL1 0.176 1.193 0.32–4.43 0.79
2DL2 − 0.740 0.477 0.15–1.48 0.20
2DL3 − 0.588 0.555 0.12–2.52 0.44
2DL4 − 1.399 0.247 0.046–1.31 0.10
2DL5A − 2.361 0.094 0.008–1.121 0.06
2DL5B − 0.155 0.856 0.23–3.15 0.81
2DS1 − 0.035 0.965 0.21–4.25 0.96
2DS2 0.737 2.089 0.65–6.70 0.21
2DS3 − 0.477 0.620 0.17–2.16 0.45
2DS4 − 0.255 0.775 0.25–2.32 0.65
2DS5 0.273 1.314 0.30–5.58 0.71
3DL1 − 1.517 0.219 0.046–1.03 0.056
3DL2 0.913 2.491 0.34–18.27 0.36
3DL3 0.493 1.637 0.22–11.98 0.62
3DS1 0.105 1.110 0.33–3.70 0.86
2DP1 − 0.353 0.702 0.12–3.84 0.68
3DP1 − 1.022 0.360 0.063–2.07 0.25
3DP1003 − 0.123 0.884 0.10–7.21 0.90
LAAS subtype
2DL1 − 0.24 0.786 0.18–3.46 0.751
2DL2 1.066 2.903 0.79–10.54 0.105
2DL3 0.91 2.486 0.33–18.84 0.378
2DL4 2.22 9.214 0.97–87.79 0.054
2DL5A 2.05 7.782 0.57–106.84 0.125
2DL5B − 0.50 0.605 0.13–2.70 0.510
2DS1 − 0.68 0.502 0.09–2.80 0.433
2DS2 − 1.07 0.341 0.09–1.27 0.109
2DS3 1.24 3.464 0.79–15.19 0.100
2DS4 0.43 1.552 0.43–5.57 0.500
2DS5 − 1.16 0.312 0.048–2.03 0.224
3DL1 0.88 2.419 0.38–15.33 0.348
3DL2 − 1.031 0.357 0.02–4.45 0.424
3DL3 − 0.829 0.437 0.026–7.33 0.565
3DS1 − 0.244 0.783 0.19–3.09 0.727
2DP1 − 0.053 0.948 0.099–9.06 0.963
3DP1 0.771 2.161 0.20–22.5 0.519
3DP1003 1.096 2.993 0.21–43.26 0.421
Cardioembolic subtype
2DL1 − 0.226 0.797 0.18–3.48 0.76
2DL2 0.144 1.155 0.31–4.28 0.83
2DL3 0.844 2.325 0.43–12.54 0.32
2DL4 0.801 2.227 0.35–14.04 0.39
2DL5A 2.81 16.672 1.23–225.4 0.03
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of KIR and HLA genes in patients with ischemic
stroke.
With regard to KIR gene frequency in relation to
TOAST subtype, we observed a higher frequency in
subjects with LAAS subtype in comparison with sub-
jects with other TOAST subtypes of 2DL3, 2DL4,
3DL2, 3DL3, and 3DP1*003 KIR genes, whereas with
regard to interaction KIR-HLA, we observed a higher
frequency of 2DL1HLAC1 in subjects with cardioem-
bolic stroke subtype.
Multiple logistic regression analysis considering vari-
ables predictive of TOAST ischemic stroke showed a
significant association between 2DL5A and 3DL1 KIR
genes and cardioembolic stroke, whereas with regard to
HLA allele interaction, only HLA-C1 allele was signifi-
cantly associated to cardioembolic stroke. We also ob-
served a possible trend toward significance with regard
to a possible protective role of HLA-A-Bw4 HLA allele
and of 2DS2-HLA-C2 interaction HLA-KIR towards
LAAS subtype of stroke.
These findings seem to be not fully consistent with
the findings of this study of a prevailing KIR gene
frequency of patients with acute ischemic stroke as
predominantly as excitatory, whereas the analysis be-
tween TOAST subtypes such as atherosclerotic and
cardioembolic ones shows an association with pre-
vailing inhibitory genes such as 2DL3, 2DL4, 3DL2,
and 3DL3 KIR genes and a prevailing inhibitory
HLA-KIR interaction such as 2DL1HLAC1.
It explains that the relationship between KIR genes
and stroke subtypes is not easy to explain, and prob-
ably future studies with a larger sample of subjects
with each stroke subtype may be helpful to better
characterize the relationship between HLA-KIR
genetic background and clinical subtype of ischemic
stroke.
Nevertheless, some possible explanations may be pos-
tulated to explain the non-consistent findings of our two
sets of analysis with regard to the association between
KIR and HLA genes with stroke and stroke subtypes.
Several evidences support the concept that migration of
inflammatory cells to the vascular wall is intimately associ-
ated with the cause of vascular conversion leading to ath-
erosclerosis [39–41]. Inflammatory cells in cerebral vessel
have been reported as capable of responding to cardiovas-
cular risk factors for human stroke such as hypertension,
hyperlipidemia, diabetes mellitus, obesity, and smoking in
subjects with cerebrovascular disease. The role of inflam-
matory cell in stroke pathogenesis has recently been re-
ported, but the role of KIR-HLA interaction to regulate
migration and response of inflammatory cells such as NKs
and T cell in development of a cerebral artery thrombosis
due to atherosclerotic and cardioembolic mechanism is
unknown.
HLA class I molecules and the KIR serve as ligand and
receptor. Certain combinations of KIRs and HLA mole-
cules can transmit activating or inhibitory signals to regu-
late the function of NK cells.
HLA-C alleles can be placed into one of two categories,
C1 and C2, which are recognized differentially by the KIR re-
ceptors. NK cells that express KIR2DL2 and KIR2DL3 inter-
act with HLA-C1 allotypes, whereas KIR2DL1 and KIR2DS1
interact with HLA-C2 allotypes [42–46]. Our findings of a
higher prevalence of HLA-C1 HLA alleles and of 3DL1 KIR
gene in subjects with cardioembolic stroke could underline
the prevalent role of inhibitory mechanisms of NKs and T
cell regulating, whereas an excitatory pathway seems to be
more involved in subjects with atherosclerotic strokes.
Table 6 Logistic regression model to predict TOAST subtype of acute ischemic stroke in relation of prevalence of KIR haplotypes
(Continued)
Variable Beta Exp(B) 95% confidence interval for Exp(B) p value
2DL5B 0.657 1.928 0.45–8.21 0.37
2DS1 0.723 2.060 0.39–10.77 0.39
2DS2 − 0.264 0.768 0.21–2.83 0.69
2DS3 − 0.169 0.845 0.19–3.64 0.82
2DS4 0.058 1.060 0.31–3.65 0.92
2DS5 0.379 1.461 0.31–6.97 0.635
3DL1 2.17 8.791 1.41–54.6 0.02
3DL2 − 0.92 0.395 0.04–3.61 0.41
3DL3 − 0.88 0.413 0.04–4.06 0.44
3DS1 0.010 1.010 0.26–3.90 0.98
2DP1 0.75 2.119 0.31–14.59 0.44
3DP1 1.667 5.299 0.76–36.71 0.09
3DP1003 0.001 1.001 0.089–11.32 0.99
LAAS large artery atherosclerotic stroke, KIR killer cell immunoglobulin-like receptor, HLA human leukocyte antigen
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Table 7 Logistic regression model to predict TOAST subtype of acute ischemic stroke in relation of prevalence of HLA allele and of
HLA-KIR interactions
Variable Beta Exp(B) 95% confidence interval for Exp(B) p value
Lacunar subtype
HLA-A-Bw4 1.04 2.853 0.86–9.39 0.08
HLA-C1 − 1.24 0.28 0.07–1.15 0.07
HLA-C2 − 0.29 0.74 0.21–2.61 0.65
HLA-B-Bw4T − 0.82 0.43 0.11–1.73 0.23
HLA-B-Bw4I − 1.132 0.32 0.03–3.15 0.33
2DL2-HLA-C1 − 0.50 0.60 0.16–2.19 0.44
2DL3-HLA-C1 − 0.64 0.52 0.17–1.57 0.25
2DS2-HLA-C1 0.49 1.647 0.59–4.57 0.33
2DS-2HLA-C2 0.76 2.156 0.67–6.85 0.19
2DL2-HLA-C2 0.06 1.063 0.31–3.56 0.92
2DS1-HLA-C2 − 0.73 0.48 0.08–2.86 0.42
2DL1-HLA-C1 0.18 1.197 0.28–4.96 0.80
2DL1-HLA-C2 − 0.24 0.78 0.17–3.49 0.75
aplotipoHLA-A − 0.38 0.68 0.25–1.79 0.44
LAAS subtype
HLA-A-Bw4 − 1.322 0.26 0.07–1.01 0.05
AB haplotype − 0.13 0.87 0.27–2.8 0.82
HLA-C1 0.31 1.37 0.29–6.36 0.68
HLA-C2 − 0.46 0.62 0.14–2.66 0.52
HLA-B-Bw4T 1.006 2.73 0.59–12.53 0.19
HLA-B-Bw4I 0.87 2.4 0.19–30.19 0.49
2DL2-HLA-C1 0.10 1.1 0.26–4.66 0.89
2DL3-HLA-C1 0.48 1.63 0.47–5.60 0.43
2DS-2HLA-C1 − 0.89 0.4 0.12–1.33 0.13
2DS2-HLA-C2 − 1.35 2.58 0.06–1.03 0.05
2DL2-HLA-C2 − 0.12 0.88 0.22–3.41 0.85
2DS1-HLA-C2 0.79 2.2 0.31–15.67 0.43
2DL1-HLA-C1 − 1.46 0.23 0.03–1.64 0.14
2DL1-HLA-C2 − 0.01 0.98 0.19–5.03 0.98
Cardioembolic subtype
HLA-A-Bw4 − 0.48 0.61 0.15–2.40 0.48
AB-haplotype − 1.18 0.3 0.08–1.15 0.08
HLA-C1 2.36 10.63 2.10–53.78 0.004
HLA-C2 1.24 3.48 0.71–17.07 0.12
HLA-B-Bw4T 0.96 2.63 0.51–13.38 0.24
HLAB-B-w4I 2.135 8.45 0.71–100.69 0.09
2DL2-HLA-C1 0.64 1.91 0.43–8.33 0.38
2DL3-HLA-C1 0.67 1.96 0.52–7.29 0.31
2DS2-HLA-C1 0.26 1.3 0.37–4.56 0.67
2DS2-HLA-C2 − 0.05 0.95 0.21–4.14 0.94
2DL2-HLA-C2 − 0.29 0.74 0.18–3.05 0.68
2DS1-HLA-C2 0.68 1.97 0.27–14.06 0.49
2DL1-HLA-C1 0.60 1.82 0.40–8.31 0.43
2DL1-HLA-C2 0.78 2.19 0.39–12.19 0.36
LAAS large artery atherosclerotic stroke, KIR killer cell immunoglobulin-like receptor, HLA human leukocyte antigen
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Nevertheless, recent reports indicate that the inter-
action of the inhibitory KIR with the HLA ligand not
only functions to inhibit NK cell activation, but also
serves to prime the particular NK cell for activation in
the absence of self [47, 48].
An individual NK or T-lymphocyte cell may simultan-
eously express multiple different receptors, each of
which may have different ligand specificities. Further-
more, in addition to the known inhibitory role of KIR at
the effector level, coinheritance of inhibitory KIR2DL3
and its cognate ligand HLA-CAsn-80 is associated with
increased clearance of hepatitis C virus [49]. These find-
ings indicate that in addition to their inhibitory function
at the effector level, another critical role for these
MHC-specific inhibitory receptors was recently de-
scribed [50], a process that these authors have termed
licensing and that involves a positive role for
MHC-specific inhibitory receptors and requires the cyto-
plasmic inhibitory motif originally identified in effector
responses after interactions of inhibiting KIR receptor
with its ligand thus resulting in an immunoinflammatory
activation. This issue could also explain our findings of
association between inhibitory KIR genes and inhibitory
KIR-HLA interactions in subjects with atherosclerotic
subtype of stroke.
Licensing process of NKs and T cells may probably
help to explain different effects of KIR and HLA reper-
toire in different subtype of strokes but future studies
addressed to analyze these differences in larger sample
of subjects with acute ischemic stroke may contribute to
add further advances about this issue.
Limitations
The main limitation of this study lies in its cross-sectional
nature, making it impossible to dissect the temporal rela-
tion between genetic background and progression of cere-
brovascular disease.
Another limitation is due to the fact that CD4
+CD28null T cells variably express receptors of the killer
immunoglobulin-like receptor (KIR) family; nevertheless,
we do not perform T cell cloning and KIR phenotyping
of T cell clones on total RNA extracted from T cell clone
with an evaluation of different KIR gene transcripts and
the encoded proteins as CD158 [51].
Conclusions
Our study showed that subjects with acute ischemic
stroke in comparison with subjects without stroke were
more likely to have a higher frequency of 2DL3, 2DL4,
2DL5B, 2DS2, 2DS4, and 3DP1 KIR genes and a signifi-
cantly lower frequency of HLA-B-Bw4I allele. It explains
that the prevailing KIR phenotype of patients with acute
ischemic stroke is predominantly as excitatory consist-
ently with previous findings in patients with coronary
acute syndrome. Our findings concerning KIR genotyp-
ing and evaluation of peripheral percentage of CD4+
and CD28null cells in subjects with acute ischemic stroke
may offer useful information in order to better under-
stand genetic determinants of inflammatory pathogen-
esis of ischemic stroke and to offer possible future
prognostic and therapeutic tools.
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